Clinical Trial Update: Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults [Phase 3]

View source ↗

Summary

An open-label Phase 3 safety extension evaluated long-term safety and tolerability of vortioxetine at 2.5, 5, and 10 mg in adults with Major Depressive Disorder…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Vortioxetine (vortioxetine)

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED | Results posted: 2014-04-01